[Clinical evaluation of CA-50 in cases with colorectal cancer].
Serum CA-50 has been evaluated in 67 healthy donors and in 46 patients with a colorectal cancer by an enzyme immunoassay (EIA Kit, Mitsui pharmaceuticals, Inc.). The mean value of the healthy donors (n = 67) was 10.6 +/- 6.1 U/ml and for patients with a colorectal cancer 31.7 +/- 55.2 U/ml. Both in healthy donors and in patients, the mean value was found to be higher in females than males. The overall sensitivity in the colorectal cancer patients was 26.1 percent, the percentages for those in stage I, 20, II, 9.1, III, 40, IV, 20, and V, 50% respectively. In a correlation between serum CA-50 and CA 19-9, the correlation coefficient was 0.82 (p less than 0.01), and in between CA-50 and CEA, 0.51 (p less than 0.01). Thus a combination assay among CA-50, CA 19-9, and CEA has proved to be of significant value in cases of a colorectal cancer.